265 related articles for article (PubMed ID: 27112188)
1. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
[TBL] [Abstract][Full Text] [Related]
2. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
3. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A; Stock S; Stollenwerk B; Müller D
Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
Morais J; Aguiar C; McLeod E; Chatzitheofilou I; Fonseca Santos I; Pereira S
Rev Port Cardiol; 2014 Sep; 33(9):535-44. PubMed ID: 25241380
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting.
Hori M; Tanahashi N; Akiyama S; Kiyabu G; Dorey J; Goto R
J Med Econ; 2020 Mar; 23(3):252-261. PubMed ID: 31687870
[No Abstract] [Full Text] [Related]
9. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
10. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
12. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Briere JB; Bowrin K; Wood R; Roberts J; Tatarsky B
J Med Econ; 2017 Jun; 20(6):599-605. PubMed ID: 28151036
[TBL] [Abstract][Full Text] [Related]
13. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
14. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
15. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
Bowrin K; Briere JB; Fauchier L; Coleman C; Millier A; Toumi M; Clay E; Levy P
PLoS One; 2020; 15(1):e0225301. PubMed ID: 31978044
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
Liu L; Hong D; Ma K; Lu X
J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
[TBL] [Abstract][Full Text] [Related]
18. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]